CL2021000316A1 - Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso - Google Patents

Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso

Info

Publication number
CL2021000316A1
CL2021000316A1 CL2021000316A CL2021000316A CL2021000316A1 CL 2021000316 A1 CL2021000316 A1 CL 2021000316A1 CL 2021000316 A CL2021000316 A CL 2021000316A CL 2021000316 A CL2021000316 A CL 2021000316A CL 2021000316 A1 CL2021000316 A1 CL 2021000316A1
Authority
CL
Chile
Prior art keywords
bcma
binding proteins
multispecific binding
bind
cancer
Prior art date
Application number
CL2021000316A
Other languages
English (en)
Inventor
Asya Grinberg
William Haney
Bianka Prinz
Bradley M Lunde
Mitchell Bigelow
Gregory P Chang
Ann F Cheung
Nicolai Wagtmann
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of CL2021000316A1 publication Critical patent/CL2021000316A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Se describen proteínas de unión multiespecíficas que se unen y matan células cancerosas humanas, así como composiciones farmacéuticas y métodos terapéuticos útiles para el tratamiento del cáncer. El cáncer puede ser un cáncer que expresa el antígeno de maduración de linfocitos B (BCMA). Las proteínas de unión multiespecíficas proporcionadas en la presente exhiben alta potencia y lisis máxima de células objetivo en comparación con anticuerpos monoclonales antiBCMA.
CL2021000316A 2018-08-08 2021-02-05 Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso CL2021000316A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862716207P 2018-08-08 2018-08-08

Publications (1)

Publication Number Publication Date
CL2021000316A1 true CL2021000316A1 (es) 2021-07-30

Family

ID=69413838

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000316A CL2021000316A1 (es) 2018-08-08 2021-02-05 Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso

Country Status (19)

Country Link
US (2) US20210317223A1 (es)
EP (1) EP3833392A4 (es)
JP (1) JP2021533169A (es)
KR (1) KR20210043602A (es)
CN (1) CN112823022A (es)
AR (1) AR114544A1 (es)
AU (1) AU2019318083A1 (es)
BR (1) BR112021002072A2 (es)
CA (1) CA3108427A1 (es)
CL (1) CL2021000316A1 (es)
CO (1) CO2021001410A2 (es)
EA (1) EA202190468A1 (es)
IL (1) IL280512A (es)
MA (1) MA53293A (es)
MX (1) MX2021001524A (es)
PE (1) PE20211860A1 (es)
SG (1) SG11202100883SA (es)
TW (1) TW202019479A (es)
WO (1) WO2020033630A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20220278A1 (es) 2018-02-08 2022-02-25 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d
AU2021339005A1 (en) * 2020-09-11 2023-04-06 Bristol-Myers Squibb Company Combination therapy for cancer
WO2023011431A1 (zh) * 2021-08-03 2023-02-09 江苏先声药业有限公司 一种cd16抗体及其应用
WO2023107956A1 (en) * 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2934577A1 (en) * 2012-12-19 2015-10-28 Adimab, LLC Multivalent antibody analogs, and methods of their preparation and use
KR20180042271A (ko) * 2015-08-03 2018-04-25 잉맵 에스에이알엘 Bcma에 대응하는 단일클론 항체
JP7082604B2 (ja) * 2016-03-21 2022-06-08 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性および多機能性分子ならびにその使用
US11851491B2 (en) * 2016-11-22 2023-12-26 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
AU2018219348A1 (en) * 2017-02-10 2019-08-29 Dragonfly Therapeutics, Inc. Proteins binding BCMA, NKG2D and CD16

Also Published As

Publication number Publication date
PE20211860A1 (es) 2021-09-21
KR20210043602A (ko) 2021-04-21
MA53293A (fr) 2021-11-17
CN112823022A (zh) 2021-05-18
MX2021001524A (es) 2021-04-19
SG11202100883SA (en) 2021-02-25
IL280512A (en) 2021-03-25
CA3108427A1 (en) 2020-02-13
JP2021533169A (ja) 2021-12-02
AU2019318083A1 (en) 2021-02-25
CO2021001410A2 (es) 2021-05-10
US20220089760A1 (en) 2022-03-24
EP3833392A4 (en) 2022-05-18
EP3833392A1 (en) 2021-06-16
US20210317223A1 (en) 2021-10-14
AR114544A1 (es) 2020-09-16
EA202190468A1 (ru) 2021-07-06
TW202019479A (zh) 2020-06-01
WO2020033630A1 (en) 2020-02-13
BR112021002072A2 (pt) 2021-06-01

Similar Documents

Publication Publication Date Title
CL2021000316A1 (es) Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso
CL2023002108A1 (es) Proteínas unión multiespecíficas se unen a cd33, nkg2d, cd16, métodos de uso.
PE20210287A1 (es) Anti-cd25 para el agotamiento de celulas tumorales especificas
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
AR122018A1 (es) Proteínas que se unen a nkg2d, cd16 y clec12a
AR107442A1 (es) Anticuerpos contra el receptor huérfano similar al receptor tirosina quinasa 1 (anti-ror1), anticuerpos biespecíficos que se unen a ror1 y al antígeno cd3, y métodos para el tratamiento del cáncer
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
CO2020010345A2 (es) Dominios variables de anticuerpos que se dirigen al receptor nkg2d
AR120223A1 (es) Proteínas que unen nkg2d, cd16 y flt3
CL2020002036A1 (es) Terapia de combinación del cáncer que incluye proteínas de unión multiespecíficas que activan a las células asesinas naturales
CO2020001981A2 (es) Proteínas que se unen a nkg2d, cd16 y flt3
CL2020001334A1 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos. (divisional solicitud 201900999)
AR104484A1 (es) Anticuerpos anti-psma como agentes terapéuticos
EA202091974A1 (ru) Связывающие bcma антитела и их применение
EA202191769A1 (ru) Тубулизины и конъюгаты белок-тубулизин
EA202190862A1 (ru) Способы лечения
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
EA202192488A1 (ru) Антитела против tsg-6 и их применения
BR112023002116A2 (pt) Proteínas que se ligam a nkg2d, cd16 e egfr
AR112770A1 (es) Anticuerpos anti-ctla-4 y sus usos
AR127896A1 (es) Proteínas que se unen a nkg2d, cd16 y 5t4
BR112021016102A2 (pt) Moléculas de ligação a fcmr e usos das mesmas
EA202092151A1 (ru) Антитела